About Index Trending news
Analyze
Pricing
Xceleron (Chapter 11)

Xceleron (Chapter 11)

Work at Xceleron (Chapter 11)? Add yourself to this profile

Xceleron (Chapter 11)

14C AMS analytical tech & clinical design - R&D efficiency - translational science, target turnover, preclinical, Phase 0, enriched Phase I & Phase II/III
Edit Profile
More info

Elsewhere

Companies in the same industry

AnaBios Corporation AnaBios Corporation RxAdvance RxAdvance Ville Lehtonen Ville Lehtonen Dignify Therapeutics Dignify Therapeutics Pharmapod Pharmapod Chantest Chantest Viventia Bio Inc. Viventia Bio Inc. Zedi Zedira Zedi Zedira Adynxx Adynxx Harlem Biospace Harlem Biospace

Alexa global traffic share

Twitter followers

Terms of Service API Integrations Plans & Pricing
Built with ❤︎ by Datalicious ©2017
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

Overview

Funding 4
Add info
Add round
06 Feb 2012
$2,400,000
Venture capital
20 Jan 2010
Undisclosed funding
05 Dec 2006
$3,951,996
Venture capital (Series B)
25 May 2005
$3,653,122
Venture capital